Developing novel, safe and effective therapies that reset the immune system

The global health impact of Immune Regulation’s first-in-class immune resetting medicines promises to be extremely significant. Our goal is to allow patients to experience periods of remission without medication and for payers and healthcare providers to benefit from reduced hospitalisations and other disease-associated costs.

Immune Regulation: developing novel, safe and effective therapies that reset the immune system, aiming to make the lives of patients with inflammatory and immunologic diseases better

 

PIN201104 (‘1104)

Explore the potential healthcare impact of ‘1104: a first-in-class IMRAD for asthma and other inflammatory diseases.

Click here to find out more

IRL201805 (‘1805)

Explore the potential healthcare impact of ‘1805: a BiP analogue for rheumatoid arthritis with potential for Orphan Drug status for rare diseases.

Click here to find out more